Physician profile
Jacqueline Ramirez
NPI 1285854125
$8,458.45
in general payments reported to CMS, 2019-2025
31 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $1,136 · 2021: $1,029 · 2022: $1,608 · 2023: $1,352 · 2024: $1,307 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,619.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $732.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $698.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $656.00 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.83 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $484.10 | 2019-2024 | Xarelto |
| Abbvie INC. | $444.96 | 2020-2025 | |
| Pfizer INC. | $399.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $287.98 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $283.84 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $273.06 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $245.11 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $235.71 | 2020-2022 | |
| Amarin Pharma, INC. | $155.03 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.69 | 2019-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $146.17 | 2019-2022 | |
| Amgen INC. | $134.57 | 2024-2025 | Otezla, Repatha, Repatha |
| Corcept Therapeutics | $123.20 | 2022-2023 | Korlym |
| Phathom Pharmaceuticals, INC. | $117.81 | 2024-2025 | Voquezna |
| Abbott Laboratories | $107.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Optinose US, INC. | $100.71 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.87 | 2021-2023 | |
| Allergan, INC. | $74.95 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.02 | 2022 | |
| Ironwood Pharmaceuticals, INC | $67.80 | 2021-2024 | Linzess |
| Idorsia Pharmaceuticals US INC | $64.24 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $51.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $41.86 | 2023-2025 | Gimoti |
| Eisai INC. | $17.41 | 2020 | |
| Currax Pharmaceuticals LLC | $17.22 | 2021 | |
| Adamas Pharmaceuticals, INC. | $13.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.